Y-Intercept (HK)’s NovoCure NVCR Stock Holding History

Y-Intercept (HK)’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$390K	Buy	+24,426	New	+$408K	0.01%	1357
2026 Q2	–	Sell	-127,780	Closed	-$1.39M	–	2033
2026 Q1	$1.39M	Sell	127,780 -25,738	-17%	-$321K	0.03%	897
2025 Q4	$1.98M	Buy	+153,518	New	+$1.97M	0.04%	626
2025 Q3	–	Sell	-21,727	Closed	-$387K	–	1892
2025 Q2	$387K	Sell	21,727 -1,765	-8%	-$30.8K	0.01%	1285
2025 Q1	$419K	Buy	23,492 +4,723	+25%	+$107K	0.03%	778
2024 Q4	$559K	Buy	+18,769	New	+$397K	0.04%	676
2024 Q2	–	Sell	-123,939	Closed	-$1.94M	–	1757
2024 Q1	$1.94M	Buy	123,939 +56,302	+83%	+$828K	0.15%	175
2023 Q4	$1.01M	Buy	67,637 +17,254	+34%	+$231K	0.09%	317
2023 Q3	$814K	Buy	+50,383	New	+$1.45M	0.08%	380
2022 Q1	–	Sell	-5,248	Closed	-$394K	–	880
2021 Q4	$394K	Sell	5,248 -775	-13%	-$77.8K	0.09%	316
2021 Q3	$700K	Buy	+6,023	New	+$911K	0.13%	249
2021 Q2	–	Sell	-6,239	Closed	-$781K	–	810
2021 Q1	$781K	Buy	+6,239	New	+$987K	0.21%	148

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Y-Intercept (HK)'s NVCR Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in NovoCure (NVCR) in Q3 2026: 24,426 shares worth $390K. The stake represents 0.01% of the portfolio and ranks #1357 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in NVCR as recently as Q1 2026.

Y-Intercept (HK) first reported a position in NVCR in Q1 2021 and has held it in 12 quarters since. The position peaked at $1.98M in Q4 2025. 142 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

Y-Intercept (HK) held 24,426 shares of NovoCure worth $390K as of Q3 2026.
NovoCure was a new Y-Intercept (HK) position in Q3 2026.
NovoCure made up 0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1357 holding.
Y-Intercept (HK) first reported a position in NovoCure in Q1 2021 and has held it in 12 quarters since.
Y-Intercept (HK)'s NovoCure position peaked at $1.98M in Q4 2025.
142 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.